Top Ten most popular articles on Pharmafile.com this week

pharmafile | April 21, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing top ten 

Another week has whizzed round again as we race into Spring, and a breadth of stories have piqued the interests of our readers over the past week. A new partnership between Allergan and Novartis to tackle non-alchoholic steatohepatitis was big news, as was Pfizer’s new pledge to assist new start-up companies in the industry. But the topic which proved most popular has been trial failures, with both AbbVie and Circassia releasing disappointing results on their products.

Check out the week’s ten most popular articles on Pharmafile.com now!

10. Roche’s drug scores expanded FDA indication in advanced bladder cancer

Roche’s Genentech has revealed that its immunotherapy drug Tecentriq (atezolizumab) is now enjoying an expanded indication in the US after approval by the FDA for advanced bladder cancer.

9. Cannabidiol reduces seizures by half in severe epilepsy, study suggests

A new study has suggested that cannabidiol, a molecule derived from cannabis without its psychoactive effects, can prove beneficial for some sufferers of Lennox-Gastaut syndrome (LGS) in reducing seizures by up to 50%.

8. How regulators and NGOs are bringing the threat of fake medicines to light

Why is it that people are still prepared to trust the internet when it comes to their health? Ben Hargreaves examines the rise of fake medicines and the different ways in which the pharmaceutical and healthcare industries are fighting back.

7. FDA warning slams St Jude’s “inadequate response” to device failures

St Jude Medical has been hit with a warning letter from the FDA over the medical device manufacturer’s failure to address issues with its implantable defibrillators and at-home monitoring equipment.

6. Allergan and Novartis join forces to develop NASH combo therapy

Allergan and Novartis have announced a new partnership to conduct a clinical trial in the treatment area of non-alcoholic steatohepatitis (NASH), evaluating two of their treatments as a combination therapy.

5. New drug study successfully halts neurodegeneration in mice

A team of scientists have identified methods to prevent neurodegeneration in mice, leading to new hopes in the treatment of diseases such as Alzheimer’s and Parkinson’s in humans.

4. Trials and Tribulations: The impact of new clinical trial regulation in Europe

The implementation of a new regulation is on the horizon which could be revolutionary for the future of clinical trials across Europe. However, recent world events could cause considerable disruption to this progress, as Matt Fellows discovers.

3. Pfizer launches Healthcare Hub to support healthtech startups

Pfizer has announced the launch of ‘Pfizer Healthcare Hub: London’, a project that aims to help startups, focusing on the development of technology in healthcare, to grow to ‘reach more patients and providers’.

2. AbbVie’s experimental cancer drug hits wall in clinical study

AbbVie have released that two Phase 3 trials of its experimental cancer drug, veliparib, missed both of their primary endpoints.

1. Circassia stumbles with allergy treatments at clinical trial stage, again

Circassia has slumped at the Phase 2 clinical trial stage again, as its treatment for dust mite allergies was unable to improve on placebo treatment.

Related Content


Top Ten most popular articles on Pharmafile.com this week

As the year winds to a close, excitement is rising around the efficacy and availability …


Top Ten most popular articles on Pharmafile.com this week

The top ten news stories this week focus on herd immunity, as the Director of …


Pharmafile.com’s weekly COVID-19 news round-up

The coronavirus news this week focuses on the development of treatments to alleviate symptoms of …

Latest content